Should Men Get Tested?
Half of all carriers of hereditary cancer mutations are male, yet most men have never heard of germline testing. New research, new genes, and new national guidelines are changing that calculus fast.
For decades, the language of hereditary cancer genetics was implicitly female. "The breast cancer gene." Ovarian cancer syndromes. Women's health clinics. Men watched from the periphery, rarely asking whether they, too, might be carrying a ticking molecular clock. That oversight is now being corrected urgently by a convergence of genomic research, updated clinical guidelines, and a deeper understanding of how inherited mutations behave differently across sexes.
The data are unambiguous: approximately 50% of all carriers of inherited, cancer-predisposing mutations in BRCA1 and BRCA2 are male, yet the implications for men's health have been systematically under-recognized compared to female carriers. A landmark January 2025 review published in JAMA Oncology by researchers at Fred Hutch Cancer Center and the University of Washington concluded that risks to male BRCA carriers are "convincing," spanning prostate, pancreatic, and breast cancers, and called for immediate adoption of updated national screening guidelines calibrated specifically for men.
The BRCA Problem Men Don't Know They Have
BRCA1 and BRCA2 are tumor-suppressor genes involved in repairing damaged DNA. When a pathogenic variant, a mutation that disrupts gene function, is inherited, DNA repair becomes unreliable and cancer risk climbs sharply. According to data from the National Cancer Institute, between 19% and 61% of men carrying a harmful BRCA2 variant will develop prostate cancer by age 80, compared to roughly 10.6% of men in the general population. For BRCA1 carriers, that prostate cancer risk runs between 7% and 26%, which is still substantially elevated above baseline.
The pancreatic cancer link is equally alarming. A 2024 systematic review and meta-analysis encompassing 4,267 individuals found that first-degree relatives of pancreatic cancer patients who carry BRCA1/2 mutations face two to ten times the general population's risk of developing the disease. Pancreatic cancer, with its notoriously late-stage diagnoses and poor survival rates, is precisely the cancer where early genetic identification could save lives.
Male breast cancer, though rare, also rises dramatically with BRCA status. Roughly 1.8–7.1% of men with a harmful BRCA2 variant will develop breast cancer by age 70, compared to just 0.1% of men in the general population, a 70-fold increase at the upper range. These are not theoretical numbers; they are population-level data drawn from large international cohorts.
Half of all carriers of inherited cancer-predisposing mutations in BRCA1 and BRCA2 are males, but the implications for their health are under-recognized compared to females."
Beyond BRCA: The Expanding Genetic Landscape
BRCA1 and BRCA2 receive the most attention, but they are far from the only genes that put men at elevated cancer risk. The National Comprehensive Cancer Network (NCCN), in its Version 1.2025 Prostate Cancer Guidelines, now recommends germline testing across a panel of ten genes: the homologous recombination repair genes ATM, BRCA1, BRCA2, CHEK2, and PALB2; the DNA mismatch repair genes associated with Lynch syndrome — MLH1, MSH2, MSH6, and PMS2; and the prostate-specific gene HOXB13.
HOXB13 is particularly significant for men. In 2012, researchers first demonstrated that a recurring germline mutation called "G84E" in the HOXB13 transcription factor, which regulates gene expression in the prostate through its interaction with the androgen receptor, was strongly associated with hereditary prostate cancer in men of European ancestry. The G84E variant is now formally included in NCCN guidelines and multi-gene hereditary cancer panels. Studies show HOXB13 mutations appear in 0.7–1.4% of all prostate cancers, rising to roughly 6% of early-onset cases, making it one of the most clinically relevant prostate-specific susceptibility genes identified to date.
Lynch syndrome, caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, and PMS2), is the most common form of hereditary colorectal cancer, carrying an 80% lifetime risk of colorectal cancer in affected individuals. While colorectal cancer strikes men and women equally, male Lynch syndrome carriers also carry elevated risks for prostate cancer, pancreatic cancer, gastric cancer, urothelial malignancies, and brain tumors. Evidence published in peer-reviewed literature now links prostate cancer firmly to Lynch syndrome via demonstration of mismatch repair-defective tumors in affected men, with researchers recommending that prostate cancer be formally incorporated into Lynch syndrome diagnostic workups.
A critical companion concern is cascade testing — the process of offering genetic evaluation to biological relatives once a pathogenic variant is identified in a proband. Research published in JCO Precision Oncology describes cascade testing as an "underutilized tool for cancer prevention," noting that when a man tests positive for a BRCA2 variant, for example, each of his children has a 50% probability of carrying the same mutation, information that could guide preventive screening decisions for decades. Despite this, uptake of cascade testing remains low across the United States, representing a major gap in cancer prevention infrastructure.
The Direct-to-Consumer Testing Trap
Consumer genomic tests, sold by companies like 23andMe and Ancestry, are not substitutes for clinical germline testing. The National Cancer Institute states plainly that as of early 2024, the only FDA-approved direct-to-consumer test for inherited cancer risk evaluates just three BRCA variants common in Ashkenazi Jewish populations. Critically, approximately 80% of cancer-causing BRCA variants are missed by this approach. A man who receives a negative result from a consumer genomic test and concludes he carries no elevated hereditary cancer risk may be operating on deeply flawed information. Clinical-grade germline testing through a certified laboratory, ordered by a physician or genetic counselor, examines the full gene sequence and detects the vast spectrum of pathogenic variants that consumer tests ignore entirely.
Clinical Implications: Treatment Follows Genetics
Beyond risk stratification, germline genetics now directly informs treatment selection. Men with metastatic prostate cancer harboring BRCA1/2 or ATM mutations are candidates for PARP inhibitor therapy — a class of targeted drugs that exploit the DNA repair deficiency created by homologous recombination mutations. The prospective PROREPAIR-B study found that germline BRCA2 status is an independent prognostic factor for cancer-specific survival in prostate cancer. Men with germline BRCA1/2 mutations show worse outcomes after surgery or radiation compared to noncarriers, with 5-year cancer-specific survival of 76% versus 97% (P < .001), underscoring that mutation status does not merely predict risk but shapes the entire clinical trajectory.
This convergence of prevention, prognosis, and precision treatment makes the case for genetic testing in men not merely compelling but medically necessary for appropriate risk management. The infrastructure is catching up: approximately 50% of prostate cancer patients now meet NCCN criteria for germline testing at diagnosis, and an expanding network of hereditary cancer clinics, telegenomics platforms, and oncologist-led counseling pathways are working to close the gap between guideline recommendations and real-world practice.
For men, particularly those with a personal or family history that touches any of the cancers described here, the question is no longer whether genetics matters to their cancer risk. It does. The question is whether they will act on that knowledge before a diagnosis forces the conversation.